Omeprazole (Proton Pump Inhibitor)
Treatment for GERD
Typical Dosage: 20-40 mg daily
Effectiveness
80%
Safety Score
68%
Clinical Trials
52
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
20-40 mg daily
Time to Effect
1-2 hours for acid suppression, 1-2 weeks for full symptom relief
Treatment Duration
4-8 weeks for acute, often lifetime for maintenance
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
500(Treat 500 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$150
Side Effect Mgmt:$50
Total Annual:$230
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$8,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$306.67
Cost per Remission
$383.33
Omeprazole (Proton Pump Inhibitor) Outcomes
for GERD
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+75%
Remission Rate
+60%
Common Side Effects
Headache
+7%
Diarrhea
+5%
Abdominal pain
+5%
Nausea
+4%
Constipation
+2%
Increased risk of C. difficile infection (long-term)
+0.1%
Bone fractures (long-term)
+0.5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Omeprazole (Proton Pump Inhibitor) in GERD
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
NCT06114836RECRUITINGNA
369 participants
INTERVENTIONAL
Columbus, United States
Started: Mar 14, 2024
A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
NCT06953986RECRUITINGNA
414 participants
INTERVENTIONAL
Hyderabad, India
Started: Dec 20, 2025
Treatment of Gastroesophageal Reflux Disease in Infants
NCT06255886RECRUITINGPHASE4
96 participants
INTERVENTIONAL
Aabenraa, Denmark +2 more
Started: Oct 27, 2025
Completed Clinical Trials
13 completed trials for Omeprazole (Proton Pump Inhibitor) in GERD
Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor
NCT03793556COMPLETEDNA
72 participants
INTERVENTIONAL
Rozzano, Italy
Started: May 5, 2017
A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Treatment of Patients With Chronic GERD
NCT00182260COMPLETEDNA
216 participants
INTERVENTIONAL
Hamilton, Canada
Started: Jan 1, 2000
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
NCT00978016COMPLETEDPHASE2
460 participants
INTERVENTIONAL
Huntsville, United States +63 more
Started: Sep 1, 2009
Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy
NCT01710800COMPLETEDNA
41 participants
INTERVENTIONAL
Started: Sep 1, 2008
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
NCT02505945COMPLETEDPHASE4
152 participants
INTERVENTIONAL
Mobile, United States +20 more
Started: Jun 1, 2015
PPI Test in GP Patients
NCT00318084COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Utrecht, Netherlands
Started: Jan 1, 2003
Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis
NCT03561233COMPLETEDPHASE1
250 participants
INTERVENTIONAL
Started: May 1, 2013
Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD
NCT02670642COMPLETEDPHASE3
877 participants
INTERVENTIONAL
Feldbach, Austria +59 more
Started: Aug 1, 2001
A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors
NCT01265550COMPLETEDPHASE3
366 participants
INTERVENTIONAL
Birmingham, United States +14 more
Started: Aug 13, 2012
Study of Acid Reflux in Asthma
NCT00069823COMPLETEDPHASE3
403 participants
INTERVENTIONAL
Birmingham, United States +19 more
Started: Sep 1, 2003
Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis
NCT01389401COMPLETED
36 participants
OBSERVATIONAL
São Paulo, Brazil
Started: Jan 1, 2009
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
NCT00728481COMPLETEDPHASE2, PHASE3
51 participants
INTERVENTIONAL
Rochester, United States
Started: May 1, 2008
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
NCT02555852COMPLETED
4.24M participants
OBSERVATIONAL
Montreal, Canada
Started: Sep 1, 2011
Showing 20 of 53 total trials